CLINICAL_TRIALS
trial_result
· 2025-05-16
Clinical Trial Update: Impact of Switching to Continuous Release Dopamine Agonists [Phase 3]
Summary
Phase 3 trial evaluating outcomes after switching Parkinson's disease patients to a continuous-release dopamine agonist. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Toledo | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-05-16